B9935
BMS-345541
≥98% (HPLC), powder
Sinónimos:
N-(1,8-Dimethylimidazo[1,2-a]quinoxalin-4-yl)-1,2-ethanediamine hydrochloride
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
Fórmula empírica (notación de Hill):
C14H17N5 · HCl
Número CAS:
Peso molecular:
291.78
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
BMS-345541, ≥98% (HPLC), powder
InChI key
MIDKPVLYXNLFGZ-UHFFFAOYSA-N
SMILES string
Cl[H].Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1
InChI
1S/C14H17N5.ClH/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15;/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18);1H
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
solubility
DMSO: 18 mg/mL
H2O: insoluble
originator
Bristol-Myers Squibb
storage temp.
2-8°C
Quality Level
Categorías relacionadas
Application
BMS-345541 has been used:
- as an IκB kinase (IKK) complex inhibitor to study its effects on the interferon-γ (IFN-γ) production by natural killer (NK) cells
- as an IKK inhibitor to study its effects on the expression of eotaxin and monocyte chemoattractant protein-1 (MCP-1) mRNA in gingival fibroblasts
- as nuclear factor κB (NF-κB) pathway inhibitor to study its effects on tumor necrosis factor α (TNFα) production in human oral squamous carcinoma cells
Biochem/physiol Actions
BMS-345541 is an IKB kinase (IKK) allosteric site inhibitor.
BMS-345541 possesses anti-inflammatory properties. It also blocks the nuclear factor κB (NF-κB)-dependent transcription of pro-inflammatory cytokines. BMS-345541 possesses anti-inflammatory activity and plays a role in arresting bone erosion in certain animal models.
Features and Benefits
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Neety Sahu et al.
JCI insight, 7(20) (2022-10-05)
No disease-modifying drug exists for osteoarthritis (OA). Despite success in animal models, candidate drugs continue to fail in clinical trials owing to the unmapped interpatient heterogeneity and disease complexity. We used a single-cell platform based on cytometry by time-of-flight (cyTOF)
James R Burke et al.
The Journal of biological chemistry, 278(3), 1450-1456 (2002-10-31)
The signal-inducible phosphorylation of serines 32 and 36 of I kappa B alpha is critical in regulating the subsequent ubiquitination and proteolysis of I kappa B alpha, which then releases NF-kappa B to promote gene transcription. The multisubunit I kappa
Christina Ward et al.
Tissue barriers, 3(1-2), e982424-e982424 (2015-04-04)
NF-κB (p50/p65) is the best characterized transcription factor known to regulate cell responses to inflammation. However, NF-κB is also constitutively expressed. We used inhibitors of the classical NF-κB signaling pathway to determine whether this transcription factor has a role in
Zhiyang Chen et al.
The Journal of experimental medicine, 216(1), 152-175 (2018-12-12)
Organism aging is characterized by increased inflammation and decreased stem cell function, yet the relationship between these factors remains incompletely understood. This study shows that aged hematopoietic stem and progenitor cells (HSPCs) exhibit increased ground-stage NF-κB activity, which enhances their
Aminah Ikner et al.
The Journal of biological chemistry, 286(24), 21546-21554 (2011-04-29)
The tumor necrosis factor (TNF) superfamily member TNF-like weak inducer of apoptosis (TNFSF12, CD255) (TWEAK) can stimulate apoptosis in certain cancer cells. Previous studies suggest that TWEAK activates cell death indirectly, by inducing TNFα-mediated autocrine signals. However, the underlying death-signaling
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico